WO2018169497A1 - Spray formulation comprising cholecalciferol (vitamin d3) with improved stability - Google Patents
Spray formulation comprising cholecalciferol (vitamin d3) with improved stability Download PDFInfo
- Publication number
- WO2018169497A1 WO2018169497A1 PCT/TR2017/050101 TR2017050101W WO2018169497A1 WO 2018169497 A1 WO2018169497 A1 WO 2018169497A1 TR 2017050101 W TR2017050101 W TR 2017050101W WO 2018169497 A1 WO2018169497 A1 WO 2018169497A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- oil
- spray
- puff
- cholecalciferol
- Prior art date
Links
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title claims abstract description 142
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 title claims abstract description 60
- 229940021056 vitamin d3 Drugs 0.000 title claims abstract description 55
- 235000005282 vitamin D3 Nutrition 0.000 title claims abstract description 54
- 239000011647 vitamin D3 Substances 0.000 title claims abstract description 54
- 239000007921 spray Substances 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 238000009472 formulation Methods 0.000 title description 10
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 89
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 89
- 239000011710 vitamin D Substances 0.000 claims abstract description 89
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 89
- 229940046008 vitamin d Drugs 0.000 claims abstract description 89
- 239000004006 olive oil Substances 0.000 claims abstract description 18
- 235000008390 olive oil Nutrition 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003755 preservative agent Substances 0.000 claims abstract description 12
- 239000003240 coconut oil Substances 0.000 claims abstract description 10
- 235000019864 coconut oil Nutrition 0.000 claims abstract description 10
- 235000019486 Sunflower oil Nutrition 0.000 claims abstract description 8
- 239000002600 sunflower oil Substances 0.000 claims abstract description 8
- 239000010685 fatty oil Substances 0.000 claims abstract description 7
- 239000008122 artificial sweetener Substances 0.000 claims abstract description 5
- 235000021311 artificial sweeteners Nutrition 0.000 claims abstract description 5
- 239000003205 fragrance Substances 0.000 claims abstract description 5
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 12
- 235000016709 nutrition Nutrition 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 10
- 229940088594 vitamin Drugs 0.000 description 21
- 229930003231 vitamin Natural products 0.000 description 21
- 235000013343 vitamin Nutrition 0.000 description 21
- 239000011782 vitamin Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 19
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 9
- 150000003722 vitamin derivatives Chemical class 0.000 description 9
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 8
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 239000000668 oral spray Substances 0.000 description 5
- 229940041678 oral spray Drugs 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 5
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 4
- 235000021318 Calcifediol Nutrition 0.000 description 4
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229960002061 ergocalciferol Drugs 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 235000001892 vitamin D2 Nutrition 0.000 description 4
- 239000011653 vitamin D2 Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- -1 vaccines Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- YUGCAAVRZWBXEQ-WHTXLNIXSA-N previtamin D3 Chemical compound C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)CCCC(C)C)\C=C/C1=C(C)CC[C@H](O)C1 YUGCAAVRZWBXEQ-WHTXLNIXSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 208000007442 rickets Diseases 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000737241 Cocos Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020590 Hypercalciuria Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- YUGCAAVRZWBXEQ-UHFFFAOYSA-N Precholecalciferol Natural products C=1CCC2(C)C(C(C)CCCC(C)C)CCC2C=1C=CC1=C(C)CCC(O)C1 YUGCAAVRZWBXEQ-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 239000008376 breath freshener Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000012787 harvest procedure Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 231100000003 human carcinogen Toxicity 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 206010020917 hypervitaminosis D Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
Abstract
This invention relates to a spray compositions comprising vitamin D in natural fatty oil, preferably olive oil, sunflower oil and coconut oil having no alcohol, sugar, artificial sweeteners, artificial fragrance, preservatives and antioxidants with improved stability properties. This product is used thereof for human beings, particularly, breast-feeding infants. This invention also provides an ease option of use by applying one puff into the mouth and the one puff comprises specific amount of vitamin D3.
Description
SPRAY FORMULATION COMPRISING CHOLECALCIFEROL (VITAMIN D3) WITH
IMPROVED STABILITY
DESCRIPTION Technical field:
This invention relates to a stable and ease of application spray formulation comprising cholecalsiferol (vitamin D3) in natural fatty oil, preferably olive oil, sunflower oil and coconut oil; having no alcohol, sugar, artificial sweeteners, artificial fragrance and preservatives. It is used thereof for human beings, particularly, breast-feeding infants. Prior Art:
Vitamins are complex organic substances found variously in most foods and are essential in small amounts, for the normal functioning of most living organisms. For example, vitamins are a critically necessary component of the diet of higher animals, including humans. When the normal diet fails to furnish minimum quantities of essential vitamins, it is a common practice to supplement the diet by artificially inducing the required amounts into the body. Common methods of introduction include oral ingestion of tablets or liquid solutions containing the vitamins (which may require concurrent ingestion of a suitable carrier liquid such as water or other drinkable liquid to aid in swallowing the vitamin composition and washing it into the gastro-intestinal system of the human). Similarly, but less frequently, vitamins are introduced by parenteral injection. The invention relates to specifically Vitamin D. It exists in two forms as vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol). In the present invention, "vitamin D" means vitamin D3 (cholecalciferol). Its chemical name is (5Z-7E)-(3S)-9,10-seco-5,7, 10(19)- cholestatrien-3-ol. The structural formula Cholecalciferol (vitamin D3) is represented below (Formula I):
Formula (I)
Vitamin D2 is produced by plants whereas vitamin D3 is formed in human as the result of exposure to the ultraviolet radiation of sunlight in skin. Both vitamin D2 and vitamin D3 are effective in the body as transformed to 25 -hydroxy vitamin D. This form goes to the kidneys through the circulation and there turns into calcitriol, the active form of vitamin D. Vitamin D level is low in nutrients except nutrients enriched with Vitamin D and nutrients cannot meet the daily needs. When daily requirement of vitamin D for bone and muscle health cannot meet by food and sun, vitamin D supplementation is necessarily required. When vitamin D is taken orally, rapidly absorbed from the intestines and converted into active Vitamin D by the body and vitamin D needs are resolved. According to the data obtained from the scientific study, vitamin D3 is absorbed faster and more from the digestive system and exerts more powerful than vitamin D2.
For biological activity, vitamin D must go through two metabolic steps. Vitamin D is metabolized by the liver to 25 -hydroxy vitamin D [25(OH)D], which is measured in serum to reflect vitamin D nutritional status. 25 -hydroxy vitamin D intrinsically has little biological activity. The kidney metabolizes 25 -hydroxy vitamin D into the active hormone, 1,25-dihydroxyvitamin D, which affects calcium transport across cell membranes. The body, according to its mineral requirements, carefully regulates production and breakdown of 1,25-dihydroxyvitamin D to regulate plasma calcium concentrations. Very few foods naturally contain vitamin D. Mellanby, J. Physiol (London) volume 52 (1919), instituted the idea that an artificial supplement, cod-liver oil, contained an agent that prevented rickets; the agent became known as vitamin D. Most of the vitamin D in our food is supplementary, synthetic material, which is either in the form of vitamin D3, the form naturally produced in animals, or it can be vitamin D2, which is derived from a plant steroid.
Vitamin D has been recognized as essential to health. It appears to increase the efficiency of the intestines to absorb calcium and also mobilizes calcium from bone tissue when required. Both deficiency and sufficiency of vitamin D have negative results, such as excessive vitamin D intake has been known as toxic. On the other hand, vitamin D deficiency results in impaired bone mineralization and leads to bone softening diseases such as rickets and osteoporosis, and may also be a contributing factor to high blood pressure, tuberculosis, cancer, heart disease, stroke, periodontal disease, MS, seasonal affective disorder and memory loss. Vitamin D deficiency is commonly observed in children, the aged and those of lower socio-economic status. Protection of vitamin D levels is important not only for calcium and phosphorus metabolism of bone, but also for general health and well-being. It is also a vitamin which is absolutely necessary in children for normal bone growth and development. Vitamin D deficiency is now recognized as a global epidemic.
The skin is the major site of cholesterol production and humans acquire vitamin D through the natural action of ultraviolet light on the skin. 7-Dehydrocholesterol, which is unstable to ultraviolet light, is normally a precursor to cholesterol. However, ultraviolet light breaks open the B-ring of the 7-dehydrocholesterol molecule to generate previtamin D3, which spontaneously isomerizes over hours and days into vitamin D3, which is also known as cholecalciferol. An unknown proportion of the vitamin D from the skin is absorbed into the circulation. Vitamin D3 is not soluble in water, and in the circulation, there is a protein that specifically binds to and carries vitamin D and its metabolites. The advantage of ultraviolet exposure is that it is natural, and has no vitamin D toxicity associated with it. The disadvantage is that the availability of ultraviolet light is unreliable, and too much of it causes sunburn or skin cancer. At northern latitudes there is often not enough ultraviolet light intensity outdoors to generate previtamin D.
In pharmacology, the international unit (IU) is a unit of measurement for the amount of a substance; the mass or volume that constitutes one international unit varies based on which substance is being measured, and the variance is based on the biological activity or effect, for the purpose of easier comparison across substances. International units are used to quantify vitamins, hormones, some medications, vaccines, blood products, and similar biologically active substances. In brief, IU is defined as a quantity of a biologic (such as a vitamin) that produces a particular biological effect agreed upon as an international standard.
Pediatric associations in Canada and the United States now strongly encourage starting vitamin D supplementation from birth onwards (Health Canada, Vitamin D supplementation for breastfed infants). Breast-feeding results in fewer infections and allergies during the first year of life compared to babies fed formula. Breast milk provides nearly optimal nutrition for newborns; however, it provides little vitamin D. Vitamin D has well-recognized effects on bone, but beyond that, better vitamin D nutrition during infancy is associated with less risk of other diseases that develop later in life. These disease reductions include less risk of juvenile diabetes, and schizophrenia (Hypponen, E., Laara, E., Reunanen, A., Jarvelin, M. R., and Virtanen, S. M. (2001) Lancet 358, 1500-1503) (McGrath, J., Saari, K., Hakko, H., Jokelainen, J., Jones, P., Jarvelin, M. R., Chant, D., and Isohanni, M. (2004) Schizophr. Res. 67, 237-245). However, because it is normally obtained through sun exposure instead of orally, vitamin D is the one nutrient that is most often deficient in breast milk (Centers for Disease Control, Vitamin D Expert Panel Meeting, October 11 - 12, 2001 Atlanta, Georgia Final Report).
In 2005, the American Academy of Pediatrics issued a new policy statement concerning breastfeeding (American Academy of Pediatrics Policy Statement 2005; Pediatrics 115; 496-506). One major change was that all breast-fed infants should receive 200 IU (5 meg) of oral vitamin D drops daily, beginning during the first 2 months of life. The older recommendation had been that vitamin
D supplementation should start at around 2 months of life. The latest American Academy of Pediatrics recommendation follows what Health Canada has been advising, that vitamin D supplementation should be from birth, with 400 IU (10 meg) of vitamin D per day (Pediatrics 2005; 115; 496-506). Moreover, Health Canada recommends that infants in the north be given 800 IU (20 meg) of vitamin D per day.
The need to provide vitamin D at an earlier age makes the problem of providing vitamin D nutrition more complicated. Smaller infants are more difficult to handle. What makes the problem worse is that the recommendations from pediatric societies and government bodies provide no detail or any method for exactly how to give vitamin D to the breast-feeding infant. They simply advise that parents should be giving vitamin D.
Parents of infants express great frustration about existing products and methods for providing infants with vitamin D, especially about the taste and the fact that infants often spit out at least some of the liquid. Direct administration of liquid vitamin D preparations is commonly done with an eyedropper, and with the infant lying on its back. One risk associated with direct administration of vitamin D solutions into the mouth is that infants can gag on, or inhale some of the liquid.
There are vitamin D drops available in oil, at 400 IU per drop in the United States (naturalhealthsupply.com). The vitamin D for this is dissolved in olive oil and/or corn oil and/or coconut or flax-seed oil. The problem with these is that the oils are comprised of long-chain unsaturated fatty-acid triglycerides that will become rancid with repeated opening of the container, they carry a flavor, and they have a greasy feel on pacifier.
EP2068885 relates to compositions comprising vitamin D in a medium-chain triglyceride medium and use thereof for human beings, particularly, breast-feeding infants, wherein said composition is applied as a single drop to a breast feeding mother's nipple, to a pacifier or a nipple of a baby bottle, and having human being suck the composition from said object surface. US4525341 discloses a method of administering a sprayable vitamin composition which may include other ingredients such as breath fresheners, flavoring agents and the like. In the development of vitamin D analogs in spray areas, spray containing vitamins are formulated with ethanol, ethanol - water mixture or water as a solvent carrier, especially many products on the market mainly with ethanol as a solvent carrier. The low viscosity of ethanol in the formulation is considered to be an advantage for the dissolution of the drug; however, since ethanol is volatile, the liquid may be concentrated in the spray pump causing variance in dosage form and also blockage and not spout spray smoothly.
This is the most important disadvantage of using ethanol in vitamin D spray formulation especially for breast-feeding infants.
Apart from the formulation, another important point is stability of vitamins in dietary supplements. A number of common physical and chemical factors affect the stability of vitamins in products (Gadient, 1986; Frye, 1994; Reddy and Love, 1999). Exposure to multiple stresses generally multiplies the effect on vitamin stability. For example, exposure to moisture through high relative humidity during storage significantly increases the rate at which vitamins are degraded by chemical reactions, such as oxidation. A similar statement could be made about exposure of vitamins to elevated temperature or strong light during storage. According to Shurson et al. (1996) vitamin D3 is sensitive to temperature, humidity, light and acidic pH; also it is highly sensitive to oxygen. Therefore there are several studies on stability of vitamin D product and it is still a necessity to develop a stable vitamin D product especially for breast-feeding infants.
Notwithstanding the above teachings of the prior art, there remains a need for a safe, convenient and efficacious method of administering nutritional or therapeutic amounts of vitamin D to a human being, particularly a breast-feeding infants. There is also a utility for adults to be able to deliver a dose of vitamin D efficiently placing the supplement directly into the mouth with a convenient way.
Accordingly, it would be highly advantageous to provide more convenient compositions and methods for introducing supplemental vitamins into the human body, particularly breast-feeding infants. Because applying vitamin D drop into the mouth or any object surface concludes unreliable dose delivering to the infant. Difficulty with administration result in lower compliance rates, consequently poor compliance results in under-dosing and ineffective treatment. These factors also diminish nutrient supplementation with vitamin D. Consequently, an object of the invention is to provide a spray containing a vitamin D analog with natural oil having no alcohol, sugar, artificial sweeteners, artificial fragrance and preservatives with improved stability properties. This product also has dose uniformity with spraying the design dose even in the first dose and after the storage time.
Description of the Invention:
The present invention relates to liquid compositions comprising vitamin D, methods for the preparation thereof, and also a spray containing a vitamin D analogue not having any conservative and providing simple application procedure with high stability.
In this invention, the compound "vitamin D" means (5Z-7E)-(3S)-9,10-seco-5,7, 10(19)- cholestatrien-3-ol also having the trivial names cholecalciferol or calciol (D3).
The invention relates to a method of administering a spray able vitamin to the human being; the vitamin D compositions can be simply sprayed into the mouth, it finds the way into the proper body processes by absorption through the mucous membranes and/or simple swallowing according to normal salivary mechanisms. The human being may be an adult or an infant.
Spray drug products contain therapeutically active ingredients (drug substances) dissolved or suspended in solutions or mixtures of excipients (e.g., preservatives, viscosity modifiers, emulsifiers, buffering agents) in non-pressurized dispensers that deliver a spray containing a metered dose of the active ingredient. The dose can be metered by the spray pump or could have been premetered during manufacture.
In this invention, the liquid carrier is pharmaceutically acceptable natural fatty oil, like olive oil, sunflower oil and coconut oil. Olive oil is a fat obtained from the olive. The composition of olive oil varies with the cultivar, altitude, time of harvest and extraction process. It consists mainly of oleic acid (up to 83%), with smaller amounts of other fatty acids including linoleic acid (up to 21%) and palmitic acid (up to 20%). Sunflower oil is the non-volatile oil compressed from the seeds of sunflower. It is a monounsaturated (MUFA)/polyunsaturated (PUFA) mixture of mostly oleic acid (omega-9) -linoleic acid (omega-6) group of oils. The oil content of the seed ranges from 22% to 36% (average, 28%): the kernel contains 45-55% oil. Coconut oil is an edible oil extracted from the kernel or meat of mature coconuts harvested from the coconut palm. It has a distinctive nutty aroma and taste. It is composed of the following fatty acids: lauric acid (48% of total), myristic acid (16%), palmitic acid (9.5%), decanoic acid (8%) and others in small amounts.
Vitamin D3 contains doses of vitamin D3 recommended by scientific medical guidelines for children and adults. When used as a food supplement with recommended doses, it does not accumulate in the body and does not cause toxic effects. In this invention, it does not lead to over- consumption because of spray form. Each puff applied to mouth provides a safe amount of vitamin D support.
The use of preservatives, like alcohols, benzoates, sorbates, and parabens is common in liquid formulations. Preservatives are effective in controlling mold, inhibiting yeast growth and protecting against bacterial proliferation, thus, finally, to allow compliance with the European Pharmacopoeia microbiological specifications (Ph. Eur. 6.7, S5.1.4) for "aqueous preparations for oral use" or "aqueous preparations for oromucosal use". Consequently most of the vitamin products contain preservatives; especially butylated hydroxyanisole (BHA) is used in vitamin products containing oil.
Butylated hydroxyanisole (BHA) is an antioxidant consisting of a mixture of two isomeric organic compounds, 2-teri-butyl-4-hydroxyanisole and 3-teri-butyl-4-hydroxyanisole. It is prepared from 4-methoxyphenol and isobutylene. It is a waxy solid used as a food additive with the E number of E320. The primary use for BHA is as an antioxidant and preservative in food, food packaging, animal feed, cosmetics, rubber, and petroleum products. BHA is commonly used in medicines. Since 1947, BHA has been added to edible fats and fat-containing foods and medicines for its antioxidant properties as it prevents rancidification of food which creates objectionable odors. Like butylated hydroxytoluene (BHT), the conjugated aromatic ring of BHA is able to stabilize free radicals, sequestering them. By acting as free radical scavengers, further free radical reactions are prevented. However, The U.S. National Institutes of Health report that BHA is reasonably anticipated to be a human carcinogen based on evidence of carcinogenicity in experimental animals. In particular, when administered in high doses as part of their diet, BHA causes papillomas and squamous cell carcinomas of the forestomach in rats and Syrian golden hamsters. The State of California, has, however, listed it as a carcinogen. Since babies and kids have much smaller bodies, any harmful foods or additives can do much more proportionate damage to them. Furthermore, breast-feeding mothers may not want to give their infants foreign liquids or compounds that are not natural for them to be taking.
In this invention, the product contains no alcohol, sugar, artificial sweeteners, artificial fragrance and preservatives; especially the product is BHA free. The spray apparatus of the present invention (including spray bottle and spray pump) material may be selected from high density polyethylene, polypropylene, metal (e.g., aluminum), glass, etc. in one or more thereof, so that the drug can get better stability. Also, the amount of vitamin D3 per puff is fixed as 400 IU, 600 IU and 1000 IU. Especially, 400 IU/puff is used for breast-feed infants (0-1 age); more than 600 IU/puff and 1000 IU/puff doses are used for adults. In the present invention, vitamin D3 is available in spray cans. According to 400 IU/puff dose recommended for breast-feed infants, it provides an ease option of use by applying one puff into the mouth and the one puff has exactly 400 IU of Vitamin D3. In spray form, transportation and storage of the product is very practical. According to Republic of Turkey Ministry of Food, Agriculture and Livestock: Regulations on Turkish Food Codex Food Supplement, maximum of 500 IU vitamin D is recommended for ages 4-10; and also maximum of 1000 IU vitamin D is recommended for ages higher than 11.
Compositions of this invention are detailed below showing examples. However, pharmaceutical compounds of this invention are not restricted to the following examples.
Example 1.
Vitamin D Oral Spray
% (a/a)
(400 IU/puff)
Olive oil 99.98553
Vitamin D3
0.01447
(Cholecalciferol)
Total 100 Crystalline vitamin D3 (cholecalciferol, United States Pharmacopea grade) was dissolved into required amount of olive oil (United States Pharmacopea grade), to make a solution containing 125 meg vitamin D per one mL of final product. It was dispensed into a spray bottle and spray pumps tightened. Example 2.
Vitamin D Oral Spray
% (a/a)
(600 IU/puff)
Olive oil 99.9783
Vitamin D3
0.02170
(Cholecalciferol)
Total 100
Crystalline vitamin D3 (cholecalciferol, United States Pharmacopea grade) was dissolved into required amount of olive oil (United States Pharmacopea grade), to make a solution containing 187.5 meg vitamin D per one mL of final product. It was dispensed into a spray bottle and spray pumps tightened.
Example 3.
Vitamin D Oral Spray
% (a/a)
(1000 IU/puff)
Olive oil 99.96383
Vitamin D3
0.03617
(Cholecalciferol)
Total 100
Crystalline vitamin D3 (cholecalciferol, United States Pharmacopea grade) was dissolved into required amount of olive oil (United States Pharmacopea grade), to make a solution containing 312.5 meg vitamin D per one mL of final product. It was dispensed into a spray bottle and spray pumps tightened.
Example 4.
Vitamin D Oral Spray
% (a/a)
(600 IU/puff)
Sunflower oil 99.9783
Vitamin D3
0.02170
(Cholecalciferol)
Total 100
Crystalline vitamin D3 (cholecalciferol, United States Pharmacopea grade) was dissolved into required amount of sunflower oil (United States Pharmacopea grade), to make a solution containing 187.5 meg vitamin D per one mL of final product. It was dispensed into a spray bottle and spray pumps tightened. Example 5.
Vitamin D Oral Spray
% (a/a)
(600 IU/puff)
Coconut oil 99.9783
Vitamin D3
0.02170
(Cholecalciferol)
Total 100
Crystalline vitamin D3 (cholecalciferol, United States Pharmacopea grade) was dissolved into required amount of coconut oil (United States Pharmacopea grade), to make a solution containing 187.5 meg vitamin D per one mL of final product. It was dispensed into a spray bottle and spray pumps tightened.
Stability Studies
The stability of a drug substance is an important factor in the manufacture of safe and effective pharmaceutical products. Stability studies are required to be submitted by any applicant seeking approval for a new pharmaceutical product. Stability study requirements are covered, for example in the United States Pharmacopeia, in the Good Manufacturing Practices (GMP) as well as in FDA and ICH Guidelines. It is known that many drugs exhibit poor or modest shelf stability. The diminution of the concentration of a drag as a result of its degradation is inherently undesirable, as it makes therapy with the drug less certain. Stability issues can be caused by environmental factors such as humidity, temperature and the like.
Furthermore, it is hypothesized that the stability of vitamin D3 decreases rapidly after the preparation has been opened because of the influence of oxygen, temperature, humidity and light exposure, leading to a significant decrease in vitamin D content.
Vitamin D3 content should be regulated due to the risk of toxicity from excessive intake. Hypervitaminosis D can occur in patients who take vitamin D supplements and are associated with hypercalcemia and other effects such as hypercalciuria, anorexia, weight loss, weakness, fatigue, disorientation, vomiting, constipation and even irreversible renal and cardiovascular damage. Due to this reason, no excess dose is used in this invention.
Most of the liquid dosage forms of vitamin D3 on market are packaged in dark glass containers that protected the product from light and oxygen. However, once the preparations are opened, they are exposed to both of these factors, making them further susceptible to oxidation and degradation of the vitamin. It has been discovered in this invention; using spray bottles having little contact with air highly prevent the oxidation and degradation of vitamin D3.
A literature search on Medline and Embase indicated that there was limited published data on the stability of oral vitamin D preparations. In one study, Huyghebaert et al. reported that cholecalciferol prepared as a liquid dose form with 0.15% Tween 80 and various stabilizers, the product was stable just for 6 months at 17 °C and for 2 months at room temperature. EP2068885 B l discloses experimental observation of potential liquids for suitability for vitamin D as stability of vitamin D is poor in water; evaporation of solvent changes concentration of vitamin D in ethanol; oxidation and rancidization occur in formulation of vitamin D with canola oil, olive oil and coconut oil.
In the development of vitamin D spray dosage form, stability was assessed under three different isothermal conditions (25 °C ± 2°C, 30°C ± 2°C and 40°C ± 2°C) in temperature-programmable control cabinets. A temperature of 25 °C ± 2°C represents ambient temperature, 30°C ± 2°C represents intermediate temperature and 40°C ± 2°C is a temperature that can be reached under extreme conditions in homes without air conditioning in the summer. The extreme condition, temperature of 40°C ± 2°C and 75 % ± 5 % RH (Relative Humidity), accelerated stability studies is carried out on vitamin D spray dosage form up to 6 months. Stability data for all examples given over 40°C ± 2°C and 75% ± 5 % relative humidity are shown in Table 1.
Even if no excess dose is used in the products explained in example 1 to 5, the results of assay determination for cholecalciferol (vitamin D3) were within the limit for 6 months period and 40°C ± 2°C, 75% ± 5 % RH humidity extreme conditions. Also, the cholecalciferol spray form products, not containing any preservatives such as BHA, were found in acceptable limits and no degradation products were observed or levels of degradation product were below the limits of quantification according to the analytical method adopted. In addition to that, all formulations were tested for microbial contamination of total viable aerobic count, total combined yeast and mould count and Escherichia coli at each month. Example 1 -5 passed microbial testing for 6 months period and 40°C ± 2°C, 75% ± 5 % RH humidity extreme conditions.
Table 1. Stability data of examples in olive oil formulations over 6 months' period and 40°C ± 2°C, 75% ± 5 % RH humidity
Mean assay determination of cholecalciferol (IU/puff)
Example 1 Example 2 Example 3 Example 4 Example 5
Time
(400 IU/puff (600 IU/puff (1000 IU/puff (600 IU/puff in (600 IU/puff (months)
in olive oil) in olive oil) in olive oil) sun-flower oil) in coconut oil)
Initial 401,3 613,5 1034,2 620,4 600,5
1 410,8 621,6 1020,3 612,6 615,3
2 402,8 625,5 1036,3 603,4 594,4
3 398,1 618,6 1016,7 615,7 605,4
4 385,6 620,4 995,7 598,5 610,6
5 391,4 627,6 1015,1 605,3 610,5
6 384,2 615,8 991,5 611,4 602,4
It is concluded that the product developed in the present invention is biologically natural in the content and it is almost safe for infant consumption. Also, the product intrinsically is not subject to rancidity, oxidation or degradation over the shelf life of the composition according to results
obtained 6 months' period of 40°C ± 2°C, 75% ± 5 % RH humidity. There is little change in assay of cholecalciferol (IU/puff) within 6 months with different oil content and dosage forms. Despite the product contains no preservative, the stability of product is provided with spray form having little contact with air. Therefore this formulation achieves the improvement of stability for the vitamin D3 spray form.
Claims
1. A stable liquid oral pharmaceutical composition in a form of a spray comprising vitamin D, or a salt thereof, in natural fatty oil having no alcohol, sugar, artificial sweeteners, artificial fragrance, preservatives and antioxidants, wherein the vitamin D is cholecalciferol (vitamin D3).
2. The composition according to claim 1 , wherein used natural fatty oil is olive oil.
3. The composition according to claim 1, wherein used natural fatty oil is sunflower oil.
4. The composition according to claim 1, wherein used natural fatty oil is coconut oil.
5. The composition according to any of the claims 1 to 4, wherein the product is BHA free.
6. The composition according to claim 1, wherein amount of vitamin D per puff is fixed in order to administer nutritional or therapeutic amounts of vitamin D.
7. The composition according to claim 6, wherein the amount of vitamin D is 400 IU, 600 IU or 1000 IU per puff.
8. The composition according to claim 7, wherein the amount of vitamin D is 400 IU/puff for breast-feeding infants.
9. The composition according to claim 7, wherein the amount of vitamin D is 600 IU and/or 1000 IU per puff for adults.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2017/050101 WO2018169497A1 (en) | 2017-03-17 | 2017-03-17 | Spray formulation comprising cholecalciferol (vitamin d3) with improved stability |
TR2017/16763A TR201716763A2 (en) | 2017-03-17 | 2017-10-30 | Spray Formulation Containing Colecalciferol (Vitamin D3) with Improved Stability |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2017/050101 WO2018169497A1 (en) | 2017-03-17 | 2017-03-17 | Spray formulation comprising cholecalciferol (vitamin d3) with improved stability |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018169497A1 true WO2018169497A1 (en) | 2018-09-20 |
Family
ID=58547782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2017/050101 WO2018169497A1 (en) | 2017-03-17 | 2017-03-17 | Spray formulation comprising cholecalciferol (vitamin d3) with improved stability |
Country Status (2)
Country | Link |
---|---|
TR (1) | TR201716763A2 (en) |
WO (1) | WO2018169497A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT202100015845A1 (en) * | 2021-06-17 | 2022-12-17 | I B N Savio S R L | VITAMIN D FORMULATION PROCESS / VITAMIN D FORMULATION PROCESS |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4525341A (en) | 1984-04-09 | 1985-06-25 | Mayor Pharmaceutical Laboratories, Inc. | Method of administering vitamins |
US20080069925A1 (en) * | 2006-09-14 | 2008-03-20 | Vieth Reinhold W | Vitamin d compositions and method of administration to a human being |
US20090060878A1 (en) * | 2007-09-04 | 2009-03-05 | The Procter & Gamble Company | Oral Compositions, Products And Methods Of Use |
DE202009013422U1 (en) * | 2009-08-22 | 2010-03-04 | Gavrilovic, Rade | astaxanthin |
GB2469754A (en) * | 2009-04-23 | 2010-10-27 | Calvin John Ross | Sub-lingual drug delivery system using a neutral oil |
AU2014201329A1 (en) * | 2013-03-08 | 2014-09-25 | Biomedica Nutraceuticals Pty Ltd | Vitamin D3 oral spray |
EP2942050A1 (en) * | 2014-05-06 | 2015-11-11 | S.I.I.T. S.r.L. - Unipersonale | A sprayable oily composition based on liposoluble vitamins of the group d and use thereof |
-
2017
- 2017-03-17 WO PCT/TR2017/050101 patent/WO2018169497A1/en active Application Filing
- 2017-10-30 TR TR2017/16763A patent/TR201716763A2/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4525341A (en) | 1984-04-09 | 1985-06-25 | Mayor Pharmaceutical Laboratories, Inc. | Method of administering vitamins |
US20080069925A1 (en) * | 2006-09-14 | 2008-03-20 | Vieth Reinhold W | Vitamin d compositions and method of administration to a human being |
EP2068885A1 (en) | 2006-09-14 | 2009-06-17 | VIETH, Reinhold W. | Vitamin d compositions and method of administration to a human being |
EP2068885B1 (en) | 2006-09-14 | 2014-11-12 | VIETH, Reinhold W. | Vitamin d compositions and method of administration to a human being |
US20090060878A1 (en) * | 2007-09-04 | 2009-03-05 | The Procter & Gamble Company | Oral Compositions, Products And Methods Of Use |
GB2469754A (en) * | 2009-04-23 | 2010-10-27 | Calvin John Ross | Sub-lingual drug delivery system using a neutral oil |
DE202009013422U1 (en) * | 2009-08-22 | 2010-03-04 | Gavrilovic, Rade | astaxanthin |
AU2014201329A1 (en) * | 2013-03-08 | 2014-09-25 | Biomedica Nutraceuticals Pty Ltd | Vitamin D3 oral spray |
EP2942050A1 (en) * | 2014-05-06 | 2015-11-11 | S.I.I.T. S.r.L. - Unipersonale | A sprayable oily composition based on liposoluble vitamins of the group d and use thereof |
Non-Patent Citations (5)
Title |
---|
D. MELLANBY, J. PHYSIOL (LONDON, vol. 52, 1919 |
HYPPONEN, E.; LAARA, E.; REUNANEN, A.; JARVELIN, M. R.; VIRTANEN, S. M., LANCET, vol. 358, 2001, pages 1500 - 1503 |
MCGRATH, J.; SAARI, K.; HAKKO, H.; JOKELAINEN, J.; JONES, P.; JARVELIN, M. R.; CHANT, D.; ISOHANNI, M, SCHIZOPHR. RES., vol. 67, 2004, pages 237 - 245 |
PEDIATRICS, vol. 115, 2005, pages 496 - 506 |
VITAMIN D EXPERT PANEL MEETING, 11 October 2001 (2001-10-11) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT202100015845A1 (en) * | 2021-06-17 | 2022-12-17 | I B N Savio S R L | VITAMIN D FORMULATION PROCESS / VITAMIN D FORMULATION PROCESS |
Also Published As
Publication number | Publication date |
---|---|
TR201716763A2 (en) | 2018-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007295888B2 (en) | Vitamin D compositions and method of administration to a human being | |
KR20150103336A (en) | Combined use of 25-hydroxy-vitamin d3 and vitamin d3 for improving bone mineral density and for treating osteoporosis | |
JP2018019691A (en) | Iron supplement composition | |
JP2011512342A (en) | Combination of vitamin D and 25-hydroxyvitamin D3 | |
WO2018169497A1 (en) | Spray formulation comprising cholecalciferol (vitamin d3) with improved stability | |
EP2942050B1 (en) | A sprayable oily composition based on liposoluble vitamins of the group d and use thereof | |
JP2016531931A (en) | Cocoa polyphenols and their use in the treatment or prevention of eosinophilic esophagitis | |
JPS6147417A (en) | Tranquilizing chewing gum | |
CN108159073A (en) | A kind of Calci-Mix | |
Sadulaev et al. | Compensation for iodine deficiency conditions with drugs based on duckweed substrate | |
KR20040063616A (en) | Agent for diet Food | |
JPS62138146A (en) | Production of solid vitamin for domestic animal | |
TR201705831A2 (en) | THE USE OF A VEGETABLE FORMULATION CONTAINING POMEGRANOUS SEED OIL TO REDUCE BLOOD FATS KNOWN AS TRIGLYCERITE | |
LV15310B (en) | Composition comprising amorphous calcium salts having osteoprotective properties |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17717531 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17717531 Country of ref document: EP Kind code of ref document: A1 |